A clinical trial update was registered on September 11, 2026, involving the compound nesiritide within the broader context of cardiac therapy research. The trial, titled "Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapy," is registered under identifier NCT07815301. Its current status is listed as not yet recruiting, and the phase is designated as not applicable. No further details on design, endpoints, or participant criteria were provided in this update. As the study has not yet begun recruiting, no outcomes, safety findings, or efficacy data are available at this time. The trial listing can be viewed on ClinicalTrials.gov under the referenced identifier. This update reflects only the registration status as of the date noted and does not indicate any results or interim findings. Readers interested in the broader research and regulatory background of nesiritide, which remains classified as an unapproved research compound, can consult the compound overview for additional context.
Trial Update: NCT07815301 on Beta-Blocker Tapering With Mavacamten Not Yet Recruiting
See the full nesiritide overview
Source: https://clinicaltrials.gov/study/NCT07815301